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Background: New national guidance on urgent referral for investigation of colorectal cancer included
faecal occult blood testing in 2015. A service evaluation of faecal immunochemical testing (FIT)
and anaemia as risk stratification tools in symptomatic patients suspected of having colorectal cancer
was undertaken.
Methods: Postal FIT was incorporated into the colorectal cancer 2-week wait (2WW) pathway for all
patients without rectal bleeding in 2016. Patients were investigated in the 2WW pathway as normal,
and outcomes of investigations were recorded prospectively. Anaemia was defined as a haemoglobin level
below 120g/l in women and 130 g/l in men.
Results: FIT kits were sent to 1106 patients, with an 80⋅9 per cent return rate; 810 patients completed
investigations and 40 colorectal cancers were diagnosed (4⋅9 per cent). FIT results were significantly
higher in patients with anaemia (median (i.q.r.) 4⋅8 (0⋅8–34⋅1) versus 1⋅2 (0–6⋅4) 𝛍gHb/g faeces in those
without anaemia; P< 0⋅001). Some 60⋅4 per cent of patients (538 of 891) had a result lower than 4𝛍g
haemoglobin (Hb) per g faeces (limit of detectability), and 69⋅7 per cent (621 of 891) had less than
10𝛍gHb/g faeces. Some 60 per cent of patients with colorectal cancer had a FIT reading of 150𝛍gHb/g
faeces or more. For five colorectal cancers diagnosed in patients with a FIT value below 10𝛍gHb/g faeces,
there was either a palpable rectal mass or the patient was anaemic. A FIT result of more than 4𝛍gHb/g
faeces had 97⋅5 per cent sensitivity and 64⋅5 per cent specificity for a diagnosis of colorectal cancer. A FIT
result above 4𝛍gHb/g faeces and/or anaemia had a 100 per cent sensitivity and 45⋅3 per cent specificity
for colorectal cancer diagnosis.
Conclusion: FIT is most useful at the extremes of detectability; strongly positive readings predict high
rates of colorectal cancer and other significant pathology, whereas very low readings in the absence
of anaemia or a palpable rectal mass identify a group with very low risk. High return rates for FIT within
this 2WW pathway indicate its acceptability.
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Introduction
Colorectal cancer is common, with over 41 000 new diag-
noses made annually in the UK1. In 2000, guidelines for
urgent referral on a 2-week-wait (2WW) pathway were
introduced, with the aim of early diagnosis by promoting
rapid assessment and investigation2. However, the cancer
detection rate within this pathway remains below 10 per
cent and more cancers are diagnosed in patients referred
via routine pathways3–6. One-third of patients referred on
a 2WW pathway have no detectable pathology, and a fur-
ther third have no pathology that mandates intervention
or treatment. More recently, National Institute for Health
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and Care Excellence (NICE) guidance (NG12) updated
and broadened the referral criteria, with a benchmark for
investigation of any symptom with a positive predictive
value for cancer greater than 3 per cent7. Colonoscopy
remains the standard investigation of the whole colon, and
is used to investigate 85–90 per cent of patients referred to
the Nottingham 2WW pathway8. However, it is expensive
and invasive, with recognized complications, and nation-
ally the pressure on endoscopy services is growing to
potentially unsustainable levels. Flexible sigmoidoscopy9
and CT colonography10 present alternatives for inves-
tigation of low-risk patients, but ideally in the context
of safe and reliable risk stratification within the 2WW
pathway11.
The Bowel Cancer Screening Programme has achieved
significant positive stage migration towards early cancer
at diagnosis, and the conversion rate from positive occult
blood testing has been shown generally to exceed the detec-
tion rate seen in 2WW pathways8. In this context, new
NICE guidance (NG12) that broadened referral criteria
and aimed to ‘rule in’ more low-risk patients by utilizing
occult blood testing was seen as a double-edged sword in
many quarters. NG12 did not specify the type of occult
blood testing that should be used; however, studies have
suggested that faecal immunochemical testing (FIT) might
be useful in symptomatic pathways12–14 and potentially
more accurate than symptoms alone in predicting which
patients need investigation for cancer15–17.
In Nottingham, 2WW referrals are not rejected as only
the referring general practitioner (GP) may retract or
downgrade a referral, in keeping with guidance on can-
cer waiting times18. Therefore, simple risk stratification
to improve clinical effectiveness within the 2WW path-
way has been a long-term aim. Data monitoring of the
straight-to-test (STT) colonoscopy pathway was estab-
lished in August 2014 to ensure clinical governance and
clinical effectiveness8. At that time, haemoglobin (Hb) con-
centration was introduced as a mandatory field for all new
2WW referrals, but compliance was poor. Anaemia was
found to identify higher-risk patients in all patient groups,
and change in bowel habit without anaemia has a predic-
tive value for colorectal cancer of less than 3 per cent in the
Nottingham 2WW pathway19.
In December 2015, as a result of NG12, a collabora-
tive ‘Getting FIT’ working group was established with
local GPs and commissioners, the Bowel Cancer Screening
Hub and Nottingham Colorectal Service. In September
2016, Nottingham City, Nottingham West, Nottingham
North and East, and Rushcliffe Commissioning Groups
commissioned Getting FIT, thereby incorporating FIT as
a triage tool in the 2WW pathway. Approximately 1000
tests were commissioned to assess the feasibility of incorpo-
rating FIT into local symptomatic pathways for colorectal
cancer.
The aim of the present study was to evaluate anaemia and
faecal haemoglobin (fHb) levels as risk stratification tools
in a 2WWpathway, and to assess FITwithin an operational
urgent colorectal cancer pathway in England.
Methods
Referral pathway service development
The STT pathway has been described in detail previously8.
In brief, every 2WW referral received is vetted jointly by a
colorectal nurse practitioner (CNP) and a consultant colo-
rectal surgeon daily. Patients considered suitable for STT
are then contacted by telephone and assessed for suitability
to ensure patient safety and appropriateness. An alterna-
tive outcome from the vetting process is review in clinic by
either a CNP or a consultant. Patients failing the telephone
vetting process (for example, not contactable, unable to
answer questions or fitness difficult to determine remotely)
are diverted to a CNP-led clinic. Patients deemed frail,
elderly or co-morbid during vetting are directed to a con-
sultant clinic, but may undergo CT before the appoint-
ment. Referrals are logged prospectively in a database as
part of the clinical governance arrangements established to
evaluate STT and consistent with Cancer Outcomes and
Services Dataset (COSD) requirements and best practice
guidance for STT pathways.
Service modification
The STT vetting process was modified to highlight
patients referred on the 2WW pathway who should
be sent a FIT kit. All patients who were not referred
with rectal bleeding were considered for FIT assessment.
The standard 2WW/STT process was not interrupted,
and FIT test results were not used to determine the vetting
outcome. Markedly raised FIT results in returned kits
were, however, used to prioritize patients for expeditious
investigation.
Data sources and cohorts
All patients referred under the 2WW pathway from
primary care for suspected colorectal cancer between
6 September 2016 and 31 August 2017 were included,
and all outcomes were censored on 22 September 2017.
Patient demographics, referral data, vetting outcomes, FIT
results and clinical outcomes for all 2WW referrals were
recorded on a NUhCLEUS software system (developed
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locally by Nottingham Colorectal Service). The data set
is maintained by specialist nurses and a dedicated audit
clerk at the Colorectal Service at Nottingham University
Hospitals NHS Trust. The results were also moni-
tored continuously for safety by project leads. Patients
referred with rectal bleeding were excluded from FIT
stratification.
Faecal immunochemical testing process
All patients referred without rectal bleeding were posted
a faecal sample collection device (OC-Sensor™; Eiken
Chemical Company, Tokyo, Japan) within 2 days of the
2WW referral being received. The device was prelabelled
with the patient’s name, National Health Service (NHS)
number, a unique laboratory ID number and a space
to add the sample date. An instruction leaflet for using
the sampling device, a letter outlining the purpose of the
test and clarifying that the results would not be used
for diagnostic purposes in isolation, and a prepaid first-class
return envelope were also included. Participants were
asked to sample their faeces according to instructions, date
the sampling device, and return it to the laboratory within
14 days of receipt of the letter.
All returned samples were logged at the receiving
laboratory and analysed for fHb using the automated
OC-Sensor™ Diana (Eiken Chemical Company) accord-
ing to manufacturer’s protocols, alongside fHb controls.
The analyser was calibrated once a month, and two levels
of control were validated at the beginning and end of each
run. Returned samples were stored in a refrigerator at
4 ∘C upon arrival, until analysis. All samples were analysed
within 1week of receipt.
Analyses were carried out in laboratories located at the
Eastern Bowel Cancer Screening Hub, Nottingham, UK.
These laboratories are accredited by the UK Accredi-
tation Service (ISO 15189) and also take part in UK
National External Quality Assessment Service external
quality-assessment schemes.
Result notifications
The results of analyses of all returned kits were for-
warded to the STT team on a weekly basis. 2WW FIT
results were reviewed continuously by the STT team.
Patients with readings of 150 μgHb per g faeces or above
were prioritized for additional contact, early appoint-
ments or expedited investigation. This cut-off was pre-
selected to be equivalent to a positive guaiac faecal occult
blood test, the only alternative in clinical practice at the
time. Clinicians could access the FIT results if they chose
to, and also receive notification when the initial clinical
decision was not to undertake whole-colon investigation
although the FIT result was 150 μgHb/g faeces or more.
Further investigation was then at the discretion of the clin-
ician and their patient.
Data analysis
Exposure and co-variables
Patients were considered to be anaemic, as defined by the
WHO20, when their Hb level was less than 120 g/l for
women or 130 g/l for in men, based on the most recent Hb
estimation within 3months before referral. Patients with-
out a recent Hb assessment before referral were unclassi-
fied for anaemia. Age was categorized as: 18–49, 50–59,
60–69, 70–79 and 80 years or above. fHb levels were deter-
mined and categorized as: above 150, 10–149⋅9, 4–9⋅9 and
less than 4 μgHb/g faeces. The lower cut-offs were chosen
as 10 μgHb/g faeces was recommended by NICE guid-
ance on quantitative FIT (diagnostic guidance DG30)16,
and 4 μgHb/g faeces was the limit of reliable detectability
on the analyser platform.
Outcome definition
Colorectal cancer and other diagnoses were determined
from investigation outcomes by reviewing endoscopy, radi-
ology and histology reports, and clinic letters.
Other significant bowel pathology was defined as inflam-
matory bowel disease, complicated diverticular disease,
adenomas requiring endoscopic follow-up (1 polyp greater
than 1 cm in size or more than 3 confirmed adenomas),
and suspicious polyps and early colorectal cancer (SPECC)
lesions requiring multidisciplinary team assessment and
urgent removal (if proven to be malignant they were
included in the colorectal cancer group). These condi-
tions were chosen as diagnoses encountered in the 2WW
pathway that usually require further intervention in sec-
ondary care.
Statistical analysis
Data were assessed for normality using histograms and the
Shapiro–Wilks test. Comparisons were made between
continuous variables using Student’s t test when nor-
mally distributed and the Mann–Whitney U test when
not normally distributed, or with ANOVA to compare
across multiple groups. Categorical data were summarized
using frequencies and percentages. Comparisons were
made between categorical data with χ2 tests. Sensitivity,
specificity, positive predictive (PPV) and negative pre-
dictive (NPV) values were calculated along with 95 per
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cent c.i. for each cut-off of FIT. A further analysis cal-
culated these for the appropriate FIT cut-off and/or
a diagnosis of anaemia, when known. Statistical analy-
sis was performed using Stata® version 15 (StataCorp,
College Station, Texas, USA). P< 0⋅050 was considered
significant.
Funding
The project was commissioned locally to enable and evalu-
ate access to FIT for local GPs. The cost of 1000 FIT tests
was accounted for in the initial business case. All four local
clinical commissioning groups (CCGs: Nottingham City,
NottinghamNorth and East, NottinghamWest and Rush-
cliffe) approved and jointly funded this service evaluation
project. The cost of each FIT test was agreed at £15⋅00
(approximately €17, exchange rate 30 November 2018) per
sample to CCGs, including postage, analysis and adminis-
tration costs.
Results
During the study period, 1891 2WW referrals were vetted
by the STT team (Fig. 1). Some 1106 referrals were deemed
suitable for FIT and were sent kits, 895 OC-Sensor™ kits
were returned (80⋅9 per cent), three patients had incom-
plete data and one kit was unanalysable. The median kit
return time was 7 (range 2–79) days, and 93⋅9 per cent of
kits (840 of 895) were returned within 14 days. The median
age of those referred was 71⋅7 (i.q.r. 62⋅6–79⋅3) years.
Faecal immunochemical test readings
Of the 895 returned kits, 891 yielded analysable
OC-Sensor™ results. Median levels of fHb were higher
in men than in women (2⋅4 (i.q.r. 0–23⋅2) versus 1⋅8
(0–14⋅8) μgHb/g faeces respectively; P= 0⋅059), but
the difference was not statistically significant despite
a significantly higher rate of colorectal cancer in men
than women across the cohort (6⋅8 versus 2⋅6 per cent;
P< 0⋅003). Median levels of fHb increased with age,
but not significantly so (P= 0⋅931) (Table 1). Colo-
rectal cancer was significantly associated with age
(P= 0⋅003).
In total, 538 (60⋅4 per cent) returns yielded a level lower
than 4 μgHb/g faeces (limit of detectability in the labo-
ratory) and 621 (69⋅7 per cent) were below 10 μg Hb/g
faeces. Seventy-two patients (8⋅1 per cent) had a level of
150 μgHb/g faeces or above.
2WW referrals received at
Nottingham Cancer Centre
STT vetting
n=1891
Non-rectal bleeding referrals sent kit
n=1106
Kits returned
n=895 (80·9%)
FIT results with
investigation outcomes
n=810
Excluded n=85
 Kit unanalysable n=1
 Incomplete data n=3
 Declined investigation or
 did not attend n=81
Excluded (rectal bleeding or
other pathway more appropriate)
n=785
Fig. 1 Flow diagram of patients in the ‘Getting FIT’ pathway,
from referral to analysis of results. 2WW, 2-week-wait; STT,
straight-to-test; DNA, did not attend; FIT, faecal
immunochemical test.
Table 1 Demographics and faecal immunochemical test levels
2WW referrals
(n=891)*
FIT result
(μg Hb/g faeces)†
Sex
M 395 (44⋅3) 2⋅4 (0–23⋅2)
F 496 (55⋅7) 1⋅8 (0–14⋅8)
Age (years)
0–59 173 (19⋅4) 0⋅4 (0–4⋅2)
60–79 512 (57⋅5) 2⋅2 (0–15⋅3)
≥80 206 (23⋅1) 4⋅8 (1⋅2–35⋅0)
*Values in parentheses are percentages; †values are median (i.q.r.). 2WW,
2-week-wait; FIT, faecal immunochemical test; Hb, haemoglobin.
Faecal immunochemical testing and diagnosis
During the study, 810 patients returned an analysable FIT
kit and also underwent investigation on the 2WWpathway;
9⋅5 per cent (85 of 895) declined investigation, did not
attend or had missing data.
Clinical outcomes of patients referred on the 2WW
pathway are summarized in Table 2. Colorectal cancers
demonstrated the highest median FIT readings, yielding
significantly higher FIT results than some other diagnosis
groups (normal, diverticular disease, piles and microscopic
colitis; P< 0⋅001), but not compared with results for other
significant bowel pathology.
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Table 2 Final diagnosis after investigation and faecal
immunochemical test results
Diagnosis
2WW referrals
(n=810)*
FIT result
(μgHb/g faeces)†
Normal 476 (58⋅8) 1⋅2 (0–5⋅2)
Cancer 40 (4⋅9) 223 (34⋅8–1334⋅7)
Other cancer 18 (2⋅2) 15⋅4 (2⋅0–170⋅2)
High-risk adenoma 45 (5⋅6) 20⋅6 (2⋅8–83⋅2)
Low-risk adenoma‡
/benign UGI lesion
168 (20⋅7) 2 (0–11⋅9)
SPECC§ 10 (1⋅2) 127 (17⋅4–898⋅6)
Colitis 22 (2⋅7) 42⋅2 (1⋅6–314⋅8)
Microscopic colitis 29 (3⋅6) 2 (0–6⋅2)
Complicated
diverticular disease
2 (0⋅2) 17⋅7 (14–21⋅4)
*Values in parentheses are percentages; †values are median (i.q.r.).
‡Deemed not to require further endoscopic follow-up. §Significant
polyps or early colorectal cancer (SPECC) include lesions considered
suspicious for cancer, discussed at a specific multidisciplinary team
meeting with a view to consideration of urgent removal. 2WW,
2-week-wait; FIT, faecal immunochemical test; Hb, haemoglobin; UGI,
upper gastrointestinal tract.
Faecal immunochemical testing and colorectal
cancer
During the study, 40 colorectal cancers (23 left-sided,
17 right-sided) were diagnosed in the population that
returned a FIT kit and were investigated. The majority
(60 per cent) had a FIT reading of 150 μgHb/g faeces or
more. Two patients had originally declined investigation
but reconsidered when counselled with their FIT results.
A further two patients initially underwent CT with intra-
venous contrast as per local protocol for older frailer
patients8; the scans were reported as normal. FIT results
of 150 μgHb/g faeces or above prompted further investiga-
tion and demonstrated colorectal cancer in both patients.
Eleven patients with colorectal cancer had FIT readings
between 10⋅0 and 149⋅9 μgHb/g faeces. Five colorectal
cancers were diagnosed in patients with a FIT result below
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Fig. 2 Colorectal cancer detection rate by presence of anaemia as
defined by WHO criteria at referral. Hb, haemoglobin.
10 μgHb/g faeces, but all had either a palpable rectal
mass (not mentioned in the referral) or were anaemic.
No colorectal cancers were detected with a FIT reading
below 2 μgHb/g faeces, although the reliability of the plat-
form at this level of fHb could not be validated in the
laboratory.
Right-sided cancers were associated with a significantly
lower FIT result than left-sided lesions (median 41⋅6 (i.q.r.
11⋅2–406⋅8) versus 286⋅8 (142–5076⋅8) μgHb/g faeces
respectively; P= 0⋅030). Inclusion of SPECC lesions did
not alter the significance of this comparison of laterality,
with right colorectal cancers and SPECC demonstrating
lower median fHb levels (61⋅2 (i.q.r. 15⋅8–403⋅4) versus
329⋅7 (71⋅8–1705⋅0) μgHb/g faeces; P= 0⋅027).
FIT results of 4 μgHb/g faeces or above demonstrated
97⋅5 per cent sensitivity and 64⋅5 per cent specificity for the
diagnosis of colorectal cancer (Table 3). FIT had an NPV
of 97⋅8 per cent and PPV of 35⋅8 per cent for colorectal
cancer using a cut-off of 150 μgHb/g faeces (Table 3). The
NPV and sensitivity rose to over 99 per cent with lower
cut-off values.
Table 3 Sensitivity, specificity, positive predictive and negative predictive values for colorectal cancer with faecal immunochemical test
cut-off values alone or with anaemia
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
FIT cut-off (μg Hb/g faeces)
≥4⋅0 97⋅5 (86⋅8, 99⋅9) 64⋅5 (61⋅1, 67⋅9) 12⋅5 (9⋅0, 16⋅7) 99⋅8 (98⋅9, 100)
≥10⋅0 87⋅5 (73⋅2, 95⋅8) 73⋅5 (70⋅2, 76⋅6) 14⋅6 (10⋅4, 19⋅8) 99⋅1 (98⋅0, 99⋅7)
≥150⋅0 60⋅0 (43⋅3, 75⋅1) 94⋅4 (92⋅6, 95⋅9) 35⋅8 (24⋅5, 48⋅5) 97⋅8 (96⋅5, 98⋅8)
FIT cut-off (μg Hb/g faeces) and/or anaemia
≥4⋅0 100 (90⋅5, 100) 45⋅3 (41⋅6, 49⋅0) 8⋅6 (6⋅1, 11⋅6) 100 (98⋅9, 100)
≥10⋅0 97⋅3 (85⋅8, 99⋅9) 51⋅7 (47⋅9, 55⋅4) 9⋅3 (6⋅6, 12⋅7) 99⋅7 (98⋅5, 100)
≥150⋅0 86⋅5 (71⋅2, 95⋅5) 61⋅3 (57⋅7, 64⋅9) 10⋅3 (7⋅12, 14⋅2) 98⋅9 (97⋅4, 99⋅6)
Values in parentheses are 95 per cent confidence intervals. PPV, positive predictive value; NPV, negative predictive value; FIT, faecal immunochemical
test; Hb, haemoglobin.
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Table 4 Colorectal cancer detection rates in different symptom groups stratified by faecal immunochemical test results
Colorectal cancer detection rate stratified
by FIT cut-off (μg Hb/g faeces) (%)
Referral symptom % of referrals* Overall risk of colorectal cancer (%) <4⋅0 4⋅0–9⋅9 10⋅0–149⋅9 ≥150⋅0
Combined symptoms† 12⋅2 6⋅1 0 0 5⋅2 41⋅7
IDA 22⋅1 8⋅4 1⋅2 15⋅0 7⋅2 30⋅4
CIBH alone 58⋅2 3⋅0 0 2⋅1 4⋅5 34⋅6
Abdominal mass 3⋅5 10⋅7 0 0 14⋅3 66⋅7
Rectal mass 4⋅0 6⋅3 0 0 50⋅0 33⋅3
*Total of 795 referrals with 15 excluded as referral criteria were unclear. †Any combination with more than one symptom. FIT, faecal immunochemical
test; Hb, haemoglobin; IDA, iron deficiency anaemia; CIBH, change in bowel habit.
Table 5 Sensitivity, specificity, positive predictive and negative predictive values for significant bowel pathology with faecal
immunochemical test cut-off values alone or with anaemia
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
FIT cut-off (μg Hb/g faeces)
≥4⋅0 81⋅4 (72⋅3, 88⋅6) 67⋅3 (63⋅7, 70⋅8) 25⋅3 (20⋅6, 30⋅5) 96⋅4 (94⋅3, 97⋅8)
≥10⋅0 75⋅3 (65⋅5, 83⋅5) 76⋅7 (73⋅4, 79⋅8) 30⋅5 (24⋅8, 36⋅8) 95⋅8 (93⋅8, 97⋅3)
≥150⋅0 37⋅1 (27⋅5, 47⋅5) 95⋅7 (93⋅9, 97⋅0) 53⋅7 (41⋅1, 66⋅0) 91⋅8 (89⋅6, 93⋅7)
FIT cut-off (μg Hb/g faeces) and/or anaemia
≥4⋅0 87⋅6 (79⋅0, 93⋅7) 47⋅2 (43⋅3, 51⋅0) 18 (14⋅5, 22⋅0) 96⋅6 (94⋅1, 98⋅3)
≥10⋅0 86⋅5 (77⋅6, 92⋅8) 54 (50⋅2, 57⋅8) 19⋅9 (16⋅1, 24⋅3) 96⋅8 (94⋅5, 98⋅3)
≥150⋅0 68⋅5 (57⋅8, 78) 62⋅6 (58⋅9, 66⋅3) 19⋅6 (15⋅3, 24⋅4) 93⋅8 (91⋅1, 95⋅8)
Values in parentheses are 95 per cent confidence intervals. PPV, positive predictive value; NPV, negative predictive value; FIT, faecal immunochemical
test; Hb, haemoglobin.
Faecal immunochemical testing and anaemia
In total, 761 patients had a valid Hb assessment for clas-
sification of anaemia, with 288 (37⋅8 per cent) presenting
with anaemia. FIT results were significantly higher
in patients with anaemia (median (i.q.r.) 4⋅8 (0⋅8–34⋅1)
versus 1⋅2 (0–6⋅4) μgHb/g faeces in those without
anaemia; P< 0⋅001. The colorectal cancer detection
rate was higher in anaemic (26 of 288, 9⋅0 per cent)
than in non-anaemic patients (11 of 473, 2⋅3 per cent)
(P= 0⋅001) (Fig. 2). Three of the 49 patients (6 per cent)
without a recent Hb test result available were diagnosed
with colorectal cancer. The sensitivity and specificity
of each FIT cut-off value and/or anaemia are shown
in Table 3.
Faecal immunochemical testing and referral
symptoms
The overall colorectal cancer detection rate in patients
referred with ‘change in bowel habit’ alone was 3⋅0 per
cent. FIT results discriminated low-risk groups with a
0 per cent colorectal cancer detection rate (fHb below
4⋅0 μgHb/g faeces) and 2⋅1 per cent detection rate (fHb
between 4⋅0 and 9⋅9 μgHb/g faeces), from high-risk
patients with a colorectal cancer detection rate of 34⋅6 per
cent (fHb 150 μgHb/g faeces or more) (Table 4). FIT val-
ues were similar in most symptom groups other than iron
deficiency anaemia, where the colorectal cancer detection
rate was 1⋅2 per cent in patients with less than 4⋅0 μgHb/g
faeces but 15⋅0 per cent in those with results between 4⋅0
and 9⋅9 μgHb/g faeces.
Faecal immunochemical testing and significant
bowel pathology
Significant bowel pathology was diagnosed in 108 patients
(13⋅3 per cent) (Table 2). The performance characteristics of
FIT alone, and FIT result and/or anaemia, for significant
bowel pathology are shown for different cut-off values
(Table 5). FIT alone had a PPV of 53⋅7 per cent at levels
of 150 μgHb/g faeces or above.
Discussion
This study demonstrates that it is possible to stratify
risk of a diagnosis of colorectal cancer within the 2WW
pathway by incorporating simple objective measures such
as anaemia and fHb levels, alongside symptoms and demo-
graphics. FIT appears to be most useful at the extremes
of the scale, and is of practical value within the 2WWpath-
way. High FIT levels identified a group with a greater than
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30 per cent risk of colorectal cancer, with four patients
called back for additional investigation in the light of this
result – diagnoses that would have beenmissed in the stan-
dard STT pathway. Arguably, use of FIT outperformed
routine clinical practice. Low or undetectable levels might
help to avoid unnecessary urgent investigation in more
than half of the referred population.
The combination of FIT and anaemia is more sensi-
tive than FIT alone, and achieves a sensitivity of 100 per
cent when compared with standard 2WW protocols in this
cohort. Anaemia is a well recognized indicator of risk in pri-
mary care for colorectal cancer21–23, but this study empha-
sizes the value of anaemia, with or without evidence of iron
deficiency, as a risk stratification tool in a local diagnos-
tic pathway for colorectal cancer19. However, the increased
risk demonstrated with respect to anaemia is specific to
symptomatic patients and not the general population. The
data also confirm that a postal system for adoption of FIT
is viable, with good uptake and acceptable time frames for
kit return.
NICE evaluation has suggested a cut-off of 10 μgHb/g
faeces for low-risk patients16, but symptomatic patients
may have colorectal cancer despite fHb readings below this
level: 12⋅5 per cent of all colorectal cancers detected in the
present cohort. This study population includes higher-risk
patients than the low-risk patients referred to in the guid-
ance. However, these findings are in keeping with ongoing
evaluations in Dundee13, where the cut-off of 10 μgHb/g
faeces has also missed colorectal cancer in patients, but all
were found to have iron deficiency anaemia.
Change in bowel habit is a subjective referral symptom,
and FIT has clear value for stratifying risk in this group of
patients. FIT appears less useful in iron deficiency anaemia,
but could still have value in guiding the choice of first test.
For example, a FIT reading of less than 4 μgHb/g faeces,
with a colorectal cancer detection rate of 1⋅2 per cent,
might prompt CT colonography instead of colonoscopy.
This study excluded use of FIT in patients with rectal
bleeding, but other studies have shown that undetectable
blood on FIT has a reliable NPV13,14. However, exclusion
of patients with rectal bleeding identifies a high-risk group
with a PPV of 35⋅8 per cent for colorectal cancer and 53⋅7
per cent for significant bowel pathology. This is potentially
more important than the ‘rule out’ functions of FIT. FIT
should not be considered a stand-alone test, but may be
combined effectively with other objective criteria that can
be complementary in 2WW pathways.
The incorporation of FIT into clinical practice poses
challenges in the context of 2WW pathways. FIT is ide-
ally a triage tool for primary care, but complex algo-
rithms are difficult to roll out and ‘safety-netting’ for
GPs is vital. Scoring systems, such as the FAST (fae-
cal haemoglobin concentration, age and sex test) score24,
which incorporate FIT alongside demographics, may be
the solution. Anaemia provides additional value in such
scoring systems; thrombocytosis may also be of value25.
Easier access to FITmay also allow diversion of large num-
bers of patients currently diagnosed with colorectal can-
cer from routine referral pathways on to 2WW pathways.
This may have a significant impact on NHS services strug-
gling with political targets. It would also be a route to
creating the endoscopy capacity that enables a screening
programme using FIT at its most effective threshold. If
such access yields an overall stage migration towards early
cancer detection, improved clinical outcomes and survival
benefits may follow.
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